Bavarian Nordic Berna GmbH – FDA 483

An FDA inspection of PaxVax Berna GmbH in Thörishaus, Switzerland, revealed significant deficiencies in quality control and manufacturing practices. Observations included inadequate investigations into foreign material and out-of-specification results, insufficient cleaning validation for freeze dryers, and poor oversight of adverse event reporting. These issues indicate potential risks to product quality and patient safety.